Rokit to launch what it calls first human kidney regeneration surgery in July (www.koreabiomed.com)

ROKIT HEALTHCARE has announced plans to launch the first human kidney regeneration surgery in July, following regulatory approval in Korea for a groundbreaking regenerative medicine clinical trial. This ambitious study aims to assess the safety and efficacy of the company's autologous omental patch technology, which utilizes AI-driven three-dimensional bioprinting and robotic surgery to potentially transform kidney treatment. ROKIT cites preclinical successes, indicating a 63 percent kidney regeneration rate, and holds relevant patents across light regions including Korea, the U.S., and Japan. The significance of this announcement lies in its potential impact on patients with chronic kidney disease (CKD), a condition that currently lacks effective regenerative treatments. By integrating advanced technologies like AI and robotics, ROKIT is not only pushing the boundaries of what's possible in regenerative medicine but also positioning itself to cater to a growing market for medical tourism across the U.S., Europe, Middle East, and Japan. As the company seeks further approvals for advanced regenerative treatments later this year, the outcomes of this clinical trial could pave the way for innovative solutions for CKD and influence future developments in AI-assisted healthcare technologies.